title: Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival.
abstract: The objectives of this study were to determine if injection of West Nile virus (WNV) into timed-pregnant mice would result in fetal infection and if administration of WNV-reactive immunoglobulin would increase dam survival and reduce fetal viral titers. Dams injected on 7.5 days post-coitus (dpc) had detectable viral titers in the placenta 10.5dpc with a mean titer of 10(4.9) 50% cell-culture infectious doses per gram of tissue (CCID(50)/g tissue). The mean placental titer increased to 10(8.6)CCID(50)/g tissue at 12.5dpc. Infectious virus was detectable 12.5dpc in 10 of 10 fetuses with a mean titer of 10(7.5)CCID(50)/g tissue. Treatment of dams (challenged with WNV on 7.5dpc) with WNV-reactive human immunoglobulin (Ig) on 8.5 and 9.5dpc resulted in a significant reduction of virus in fetuses as compared with non-reactive human Ig-treated females on 12.5dpc (P< or =0.001). Treatment also resulted in survival of dams to term. Treatment of dams with WNV-reactive human Ig on 12.5 and 13.5dpc also resulted in reduction of viral titer on 14.5dpc, indicating that later treatment may also be efficacious. This suggests that Ig treatment may be useful in treating fetal WNV infection in women.
authors.affiliation: Institute for Antiviral Research, Utah State University, Logan, UT 84322-4700, USA.
authors.forename: Justin G
authors.initials: JG
authors.lastname: Julander
authors.forename: Quinton A
authors.initials: QA
authors.lastname: Winger
authors.forename: Aaron L
authors.initials: AL
authors.lastname: Olsen
authors.forename: Craig W
authors.initials: CW
authors.lastname: Day
authors.forename: Robert W
authors.initials: RW
authors.lastname: Sidwell
authors.forename: John D
authors.initials: JD
authors.lastname: Morrey
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000627:therapeutic use*; D005260:Female; D005333:Fetus / Q000821:virology; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D018445:Infectious Disease Transmission, Vertical; D051379:Mice; D010920:Placenta / Q000821:virology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000628:therapy* / Q000821:virology; D014901:West Nile Fever / Q000150:complications / Q000276:immunology / Q000628:therapy* / Q000635:transmission; D014902:West Nile virus / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity
chemical_list: D000914:Antibodies, Viral; D007136:Immunoglobulins